Dose Dense TC + Pegfilgrastim Support for Breast Cancer

Phase 2 Completed 42 enrolled University of Wisconsin, Madison Amgen · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the feasibility of giving standard TC chemotherapy on a dose dense schedule (ddTC) as well as evaluating the nature and frequency of ddTC side effects.

Timeline

Start: 2011-06
Primary completion: 2013-04
Completion: 2013-04

Publications

Results Burkard ME, Wisinski KB, Njiaju UO, Donohue S, Hegeman R, Stella A, Mansky P, Shah V, Goggins T, Qamar R, Dietrich L, Kim K, Traynor AM, Tevaarwerk AJ. Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study. Clin Breast Cancer. 2014 Jun;14(3):205-11. doi: 10.1016/j.clbc.2013.10.018. Epub 2013 Oct 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	600 mg/m2	Intravenous
Subject	Docetaxel	Small molecule	75 mg/m2	Intravenous
Background	Pegfilgrastim	Protein / enzyme biologic	6 mg	Subcutaneous

Dose Dense TC + Pegfilgrastim Support for Breast Cancer

Summary

Timeline

Publications

Drugs

Indications